Lantern Pharma Inc. — Form 10-Q Summary
Business Context and Reporting Period
Lantern Pharma is a clinical-stage biotechnology company developing targeted oncology therapies using its RADR® artificial intelligence, machine learning, genomic, and biomarker platform. The filing covers the three and six months ended June 30, 2023, with comparative periods ended June 30, 2022. The interim financial statements are unaudited.
The portfolio includes LP-300 in a Phase 2 trial, LP-184 in a Phase 1 trial, LP-100 in clinical development, LP-284 in pre-IND development, and an antibody-drug conjugate program. The Company formed Starlight Therapeutics in January 2023 to advance LP-184’s central nervous system and brain cancer indications under the name STAR-001.
Financial Performance and Position
| Metric | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| General and administrative expense | $1.632 million | $1.406 million | $3.365 million | $2.812 million |
| Research and development expense | $3.558 million | $2.989 million | $6.111 million | $5.649 million |
| Total operating expenses | $5.190 million | $4.395 million | $9.477 million | $8.461 million |
| Loss from operations | $(5.190) million | $(4.395) million | $(9.477) million | $(8.461) million |
| Net loss | $(4.746) million | $(4.492) million | $(8.614) million | $(8.614) million |
| Net loss per share | $(0.44) | $(0.41) | $(0.79) | $(0.79) |
Because the Company had no operating revenue, gross and operating margins are not meaningful. The six-month net loss was essentially unchanged year over year, while operating expenses increased; higher interest and other income substantially offset the increase in operating loss.
| Balance Sheet Metric | June 30, 2023 | December 31, 2022 |
|---|---|---|
| Cash and cash equivalents | $28.423 million | $37.202 million |
| Restricted cash | $0.541 million | $0.541 million |
| Marketable securities | $19.526 million | $17.994 million |
| Total current assets | $51.042 million | $58.723 million |
| Working capital | Approximately $48.026 million | Approximately $55.924 million |
| Total liabilities | $3.167 million | $2.798 million |
| Long-term debt | None reported | None reported |
| Stockholders’ equity | $48.259 million | $56.038 million |
Marketable securities had a fair value of $19.526 million and included approximately $14.061 million of government, agency, and corporate debt securities and $5.465 million of mutual funds. Unrealized losses totaled approximately $0.866 million, which management did not consider to represent credit losses.
Cash Flow and Material Changes
- Net cash used in operating activities increased to $7.349 million in the first six months of 2023 from $6.060 million in the comparable period.
- Net cash used in investing activities increased to $1.418 million from $0.349 million, primarily because of increased purchases of marketable securities.
- There was no financing cash flow in the first six months of 2023. The prior-year period included $2.482 million of share repurchases, partially offset by $0.300 million from warrant exercises.
- Cash, cash equivalents, and restricted cash declined by $8.779 million to $28.964 million at June 30, 2023, compared with a $8.620 million decline in the prior-year period.
- General and administrative expense increased 16% for the quarter and 20% for the six-month period, driven primarily by payroll, professional fees, travel, and business development costs.
- Research and development expense increased 19% for the quarter and 8% for the six-month period. Increases in research studies and compensation were partly offset by lower manufacturing costs and the absence of a prior-year nonrecurring escrow expense.
- Interest income increased to $0.252 million for the six-month period from $0.077 million. Other income, net was $0.611 million compared with other expense, net of $0.230 million in the prior-year period, primarily reflecting investment income and Australian research and development tax incentives.
- Shares outstanding increased to 10,869,040 at June 30, 2023 from 10,857,040 at December 31, 2022, primarily from the issuance of 12,000 restricted shares to consultants.
Guidance, Outlook, Risks, and Unusual Items
Management expects significant and increasing operating losses for at least the next several years. Research and development spending is expected to increase as LP-300 and LP-184 clinical trials progress, LP-284 advances toward a Phase 1 trial, and LP-100 and other programs continue development. The Company does not expect meaningful product revenue unless it successfully completes development and obtains regulatory approval.
Management believes cash and cash equivalents at June 30, 2023, together with anticipated expenditures and capital commitments, will fund operating expenses and capital expenditures for at least 12 months from the filing date. However, the Company expects to require substantial additional funding to complete clinical trials and may pursue equity financing, grants, commercial credit facilities, licensing, or collaborations.
In May 2023, Lantern engaged Fortrea as lead contract research organization for the LP-300 Phase 2 and LP-184 Phase 1 trials. The Company expects substantial payments over the following 18 to 24 months for Fortrea services, clinical trial sites, and related pass-through costs. The filing does not provide a total dollar commitment for these future payments.
- Future financing may dilute existing shareholders; debt financing could create fixed obligations and restrictive covenants.
- Clinical trials may face enrollment, regulatory, manufacturing, cost, timing, efficacy, safety, and commercial-viability risks.
- The Company has no approved drug candidates and has not established a recurring revenue stream.
- Most cash balances held at financial institutions exceed the $250,000 FDIC insurance limit.
- Marketable securities are exposed to interest-rate and market-value fluctuations, including approximately $0.866 million of unrealized losses at June 30, 2023.
- The filing identifies potential risks from competition, rapidly changing technology, regulation, foreign currency exposure, inflation, and possible future infectious-disease disruptions.
- The restricted cash escrow related to the Allarity asset purchase agreement ended in July 2023, with the remaining funds expected to be released to Lantern in August 2023.
Most Important Facts for Investors to Verify
- Timing, enrollment, interim data, and costs for the LP-300 Harmonic Phase 2 trial and LP-184 Phase 1 trial.
- Regulatory progress and timing for the planned LP-284 Phase 1 trial.
- Actual cash runway after Fortrea, clinical-site, manufacturing, and other development commitments.
- Whether additional equity, debt, grant, licensing, or collaboration financing is obtained and the resulting dilution or contractual obligations.
- Whether RADR®-identified biomarkers and patient populations produce clinically meaningful efficacy and support regulatory approval.
- Future revenue potential, since the filing reports no operating revenue and no approved commercial products.
- Subsequent-period release of the $0.541 million restricted cash escrow and any related accounting or contingent payment effects.